A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Massachusetts General Hospital
Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)
Pfizer
Kezar Life Sciences, Inc.
Regeneron Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Sotio Biotech Inc.
Incyte Corporation
Tempus AI
Incyte Corporation
Taiho Oncology, Inc.
NuCana plc
NYU Langone Health
University of California, San Diego
Daiichi Sankyo
Amgen
Bristol-Myers Squibb
NRG Oncology
Daiichi Sankyo
Sanofi
ImmunoGenesis
Hutchmed
M.D. Anderson Cancer Center
NextCure, Inc.
Elevation Oncology
Kymab Limited
Checkpoint Therapeutics, Inc.
Indiana University
Incyte Corporation
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals
InflaRx GmbH
NantBioScience, Inc.
Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC
Immodulon Therapeutics Ltd
Boehringer Ingelheim
Merck Sharp & Dohme LLC
Tyme, Inc
National Cancer Institute (NCI)
BioNTech SE
Merck Sharp & Dohme LLC
Adaptimmune
NantCell, Inc.
Servier
Indiana University